Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy | MicrobiomeTrials← Back to trialsNCT06884748
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2026-05-01Est. Completion: 2027-05-01
Enrollment target: 30 participants Locations- Daniel Stein, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Acute Leukemia in RemissionMyelodysplastic SyndromesMyeloproliferative SyndromeHodgkin LymphomaLymphoma, Non-HodgkinMyelomaChronic Lymphocytic Leukemia
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic h…
Amiens, FranceEst. completion May 2030
Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…
Izmir, Turkey (Türkiye)Est. completion May 30, 2027
DysbiosisClostridium DifficilePet-Human BondingAntibiotic-Associated Colitis
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a diseas…
Philadelphia, United StatesEst. completion Sep 1, 2026